Summary

Learn more Back Search Frequent search terms: Innovation Products Career at CSL Gene therapy Our company Our company Groundbreaking Sustainability Global Leadership Team Transparency Locations Patients Patients Diseases Diseases Immunodeficiencies and autoimmune diseases Congenital and acquired coagulopathies Hereditary angioedema Alpha-1 antitrypsin deficiency Rh incompatibility Common commitment F E F E CSL Innovation Innovation Hub M600 Investigator-initiated studies Products Products Product overview Safety and production Compliance with legal requirements Careers Careers Inclusion Accessibility CSL cares about your well-being Job profiles Life in Marburg Career start Career start Internship Training dual study Trainees Frequently asked questions about careers News News Press releases Events Professional audience Partnerships Contact Global Selector Language : German Language : German Language : English Our promise: Saving lives and improving quality of life. Learn more about our company Career at CSL Behring Make a difference with your work Learn more CSL Behring News CSL Annual Results 2026 In fiscal year 2025/2026, CSL reported a net loss after taxes without restructuring costs and impairments on Aug 20, 2026 How plasma gives hope Documentation illuminates the path from donation to life-saving medicine Jul 29, 2026 Old University in Marburg shines on the Day of Rare Diseases 2026 CSL sets a strong signal in Marburg for people with rare diseases Feb 28, 2026 Germany Scholarship for students: our contribution to promoting young talent CSL Behring sets an example for talent development and educational opportunities Feb 16, 2026 CSL Half-Year Results 2026 In the first half of fiscal year 2025/2026, CSL reported a net profit after taxes without restructuring costs and Feb 12, 2026 Unavailability of Beriglobin Beriglobin Human normal immunoglobulin, 2 ml and 5 ml injection solution in pre-filled syringes: Unavailability due to Dec 19, 2025 CSL at the Pharma Summit in the Chancellery Strategically setting the course in Berlin: 5 ministries, associations, and leading companies of the pharma and MedTech industry Nov 13, 2025 Digital Health Heroes Award 2025 HAE Recognition Website awarded Nov 05, 2025 Your research matters Apply now for the Alpha-1 Science Awards 2026 Sep 03, 2025 Back Next Our focus on rare and serious diseases Our innovative medicines include a wide range of recombinant and plasma-derived products for the treatment of coagulopathies, immunodeficiencies and chronic inflammatory demyelinating polyneuropathy, as well as products for the treatment of hereditary angioedema and alpha-1 antitrypsin deficiency.

Title

CSL Behring Germany | Life-saving biotherapeutics and plasma protein biotechnology

Description

CSL Behring is a global leader in biotechnology with the goal of saving lives and improving the quality of life for patients.

Keywords

innovation, behring, news, sind, german, leadership, team, engagement, investigator, studies, language, cookie, policy, coming, selector, english

Downstreams

csl.com, linkedin.com, youtube.com

NS Lookup

A 64.239.109.1

Dates

Created 2026-10-09

Updated 2026-10-09

Summarized 2026-10-11